|Articles|August 1, 2016
- Pharmaceutical Executive-08-01-2016
- Volume 36
- Issue 8
Pharmaceutical Executive, August 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 9 years ago
Pharm Exec's 15th Annual Industry Auditabout 9 years ago
The Industry Audit: Fifteen Years Rightabout 9 years ago
Dealmaking in 2016: It’s Complicatedabout 9 years ago
Steady Hands: AmerisourceBergen's Peyton Howellabout 9 years ago
Drug Shortages Raise Economic and Ethical Challengesabout 9 years ago
The ‘Cure’-All for 21st Century Data Sharingabout 9 years ago
European Pharma and the Unified Patent Courtabout 9 years ago
An EU Referendum ... on Drug Pricing?about 9 years ago
Country Report: HungaryNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
2
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
3
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
4
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
5
